Evidence map›Paper›PMID 32761872›Full record

Trial reportInternational journal of laboratory hematology2020

Thrombin generation abnormalities in Quebec platelet disorder.

Justin G Brunet, Tanmya Sharma, Subia Tasneem, Minggao Liang, Michael D Wilson, Georges E Rivard, Catherine P M Hayward

Open access · hybridAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in International journal of laboratory hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Thrombin generation abnormalities in Quebec platelet disorder.International journal of laboratory hematology · 2020
    Trial
  2. Review
  3. Haematologica · 2026
    Article
  4. Article
  5. Multimerin-1 and cancer: a review.Bioscience reports · 2022
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Justin G BrunetDepartment of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.
Tanmya SharmaDepartment of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.
Subia TasneemDepartment of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.ORCID https://orcid.org/0000-0002-8859-4119
Minggao LiangGenetics and Genome Biology, The Hospital for Sick Children, Toronto, ON, Canada.ORCID https://orcid.org/0000-0002-4451-0921
Michael D WilsonGenetics and Genome Biology, The Hospital for Sick Children, Toronto, ON, Canada.ORCID https://orcid.org/0000-0002-4015-3066
Georges E RivardCentre Hospitalier Universitaire Sainte Justine, Montreal, QC, Canada.
Catherine P M HaywardDepartment of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.ORCID https://orcid.org/0000-0002-2843-0817
McMaster University · CACentre Hospitalier Universitaire Sainte-Justine · CAHamilton Regional Laboratory Medicine Program · CAHospital for Sick Children · CAUniversity of Toronto · CA

Funding

Institute of Circulatory and Respiratory Health 201603PJT-364832
6 · The paper itself

Abstract

introductionCalibrated automated thrombograms (CAT) with platelet-poor (PPP) and platelet-rich plasma (PRP) have provided useful insights on bleeding disorders. We used CAT to assess thrombin generation (TG) in Quebec platelet disorder (QPD)-a bleeding disorder caused by a PLAU duplication mutation that increases platelet (but not plasma) urokinase plasminogen activator (uPA), leading to intraplatelet (but not systemic) plasmin generation that degrades α-granule proteins and causes platelet (but not plasma) factor V (FV) deficiency.

methodsCalibrated automated thrombograms was used to test QPD (n = 7) and control (n = 22) PPP and PRP, with or without added tranexamic acid (TXA). TG endpoints were evaluated for relationships to platelet FV and uPA, plasma FV and tissue factor pathway inhibitor (TFPI) levels, and bleeding scores.

resultsQuebec platelet disorder PPP TG was normal whereas QPD PRP had reduced endogenous thrombin potential and peak thrombin concentrations (P values < .01), proportionate to the platelet FV deficiency (R

conclusionQuebec platelet disorder results in a platelet-specific TG defect, proportionate to the loss of platelet FV, that is improved but not fully corrected by TXA. Our study provides an interesting example of why it is important to assess both PRP and PPP TG in bleeding disorders.

Indexed as

AdultAgedFactor V DeficiencyFemaleHumansMaleMembrane ProteinsMiddle AgedThrombinMembrane ProteinsPLAU protein, humanThrombincoagulationfactor Vfibrinolysisplatelet functionprocoagulant activity

Identifiers

PMID32761872
PMCPMC7754340
OpenAlexW3048063319

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.